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Sumumarn The dacarbazine analogue CBIO-277 has been investigated for anti-tumour activity in a phase 11
study on malignant melanoma. Treatment was administered as a slow infusion of 12.000 mg m over 24 h
and repeated every 3 weeks. A total of 28 patients were entered into the study. of whom 23 were eligible for
review. A total of 64 courses was given. There was one objective partial response in 22 patients assessable for
response. The major toxicities were leucopenia and thrombocytopenia. CBIO-277 in this schedule therefore
does not appear to have major activity in melanoma.
The anti-tumour activity of triazenes was first reported in
animals in 1962 (Shealy et al., 1962). Dimethyl triazano-
imidazole carboxamide (dacarbazine. DTIC) the lead com-
pound in clinical practice. has been demonstrated to have
activity in patients with lymphomas. melanomas and sar-
comas (Beretta et al.. 1976). In vivo metabolic activation of
dacarbazine by N-demethylation is thought to be required for
anti-tumour activity (reviewed in Newell et al.. 1987) but
may not be the sole determinant of cytotoxicity. In addition
to metabolic activation. dacarbazine undergoes chemical
decomposition which is light catalysed. Protection of dacar-
bazine solutions from light has been claimed to result in
reduced systemic toxicity (Baird & Willoughby, 1978;
Koriech & Shuikla. 1981). and this is the current clinical
practice. Furthermore, murine studies suggest that the
occasional skin reactions seen in patients treated with dacar-
bazine, particularly at high doses, may have a photochemical
basis (Dorr et al., 1987). Photochemical decomposition is not
thought to contribute to the anti-tumour activity of dacar-
bazine (Newell et al., 1987; Julliard & Vernin, 1981), and
therefore a photostable analogue of dacarbazine may have
advantages over the parent drug.
The dacarbazine analogue 1-(4-carboxyphenyl)-3,3-dimethyl-
triazene, (CBIO-277) is soluble and stable in aqueous solution
at physiological pH (Wilman & Goddard, 1980). It requires
activation, similar to dacarbazine, for its anti-tumour activity
(Connors et al., 1976) but may be more readily activated in
rats (Rutty et al., 1986). These structural similarities, with
better stability in solution and possible improved metabolic
activation, led to preclinical and phase I studies with the
drug (Foster et al., 1993a, b). In human melanoma xeno-
grafts and transplantable rodent tumours, CBIO-277 showed
a spectrum of activity similar to dacarbazine (Foster et al.,
1993a). In man, the dose-limiting toxicity was nausea and
vomiting when CBI0-277 was given by short-term infusion
(up to 35 min) every 3 weeks. The maximum tolerated dose
was 6,000 mg m Tumour responses were reported in
patients with melanoma (one complete, two partial, out of 11
treated) as well as in one patient with recurrent carcinoid.
Mixed responses were seen in one further melanoma and one
sarcoma patient.
A second phase I trial modelled on the plasma pharmaco-
kinetic studies in the previous study attempted to reduce the
degree of nausea and vomiting by using a 24 h infusion
schedule (Foster et al., 1993b). It was believed that a decrease
in peak plasma levels of parent CBIO-277 might permit a
larger total drug administration over 24 h with increased
levels of the biologically active monomethyl metabolite. A
recommended dose of 12.000mgm- was determined. with
acceptable nausea and vomiting and minimal myelosupres-
sion. No tumour responses were recorded in this second
study.
On the basis of the known activity of dacarbazine against
melanoma. the 3 11 responses seen with short-term infusion
of CBIO-277 and the improved acceptability of the prolonged
infusion the 24 h schedule was investigated in a CRC phase
II study. The clinical results of that study are presented.
Patients and methods
Patients
Eligibility criteria required histologically proven malignant
melanoma with measurable disease not amenable to loco-
regional treatment and documented to have progressed
within the 2 months prior to entry into the study. Other
criteria included performance status 0-2 (WHO scale). age
75 or less, white blood cell count (WBC) 3 x 1091-' or
higher, platelets 100 x 1091-' or higher. serum bilirubin
below 20 !Lmol 1` and creatinine below 150iLmol 1-'. No
prior chemotherapy. other than a biological response
modifier given more than 4 weeks prior to study. was permit-
ted, nor was prior radiotherapy to the measurable or
evaluable disease. Patients with poor general medical risk
were excluded.
Before receiving the first course of CBIO-277 baseline
investigations included physical examination, chest radio-
graphy and other appropriate radiological studies to docu-
ment the extent of the disease. Blood chemistry (urea.
creatinine, uric acid, electrolytes, calcium, glucose, bilirubin,
alkaline phosphatase and ALT) and full blood counts
(haemoglobin, white cell and differential, platelets) were
recorded before treatment and weekly during treatment.
Clinical assessment of evaluable lesions was documented
before each course and on termination of therapy. Evalua-
tion for side effects and response followed strict WHO
criteria (WHO, 1979). In patients with more than one evalu-
able lesion the least responsive indicator lesion determined
the overall response assessment.
The study was approved by the Medical Ethics Commit-
tees of the participating centres and informed consent was
obtained from each patient.
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Drug
CB1O-277 (MW = 215) was formulated as the sodium salt as
a lyophilised pyrogen- and preservative-free powder in
1,000 mg vials by the Developmental Therapeutics Program.
National Cancer Institute, Bethesda, MD, USA.
For each course the patient's total dose was calculated and
then half was reconstituted (50mgml-') and placed in a
1,000 ml 0.9% normal saline bag and infused over 12 h. The
remaining half of the dose was then reconstituted and given
over the second 12 h. The infusion was carried out in this
manner because the drug preparation contained no bacterio-
static agent.
Treatment schedule
A dose of 12,000 mg m- was selected on the basis of the
phase I study given as a slow infusion of 24 h (Foster et al.,
1993b).
All patients were given standard antiemetics including
metoclopramide, chlorpromazine. lorazepam and recently
ondansetron.
Provided that there was no disease progression, courses
were repeated every 21 days. Dose modification was indicat-
ed on the basis of haematopoietic toxicity with reductions by
25% for WBC <2 x 1091-' and platelets <75 x 1091-' on
the day of the next treatment or of 50% if morbidity for
infection or haemorrhage. Dose delays were at the discretion
of the individual clinicians.
Data collection and initial analysis were carried out by the
CRC Phase I/II Trials Office and subsequently reviewed by
the two study chairmen.
Results
A total of 28 patients was entered into the study, ofwhom 23
were eligible for review. The five exclusions were due to an
incorrect histological diagnosis (1). prior chemotherapy (2)
and a raised serum bilirubin on entry (2). Patient characteris-
tics are shown in Table I. One patient refused to continue in
the study after the first course and was not assessable for
response but has been included in this report. All the remain-
ing 22 patients were assessable for toxicity and response after
at least one full course of the drug.
A total of 64 courses of the drug were given with a median
of 2 and a range of 1-6. There was a dose reduction in six
courses in four patients (neutropenic septicaemia, 3; severe
leucopenia and thrombocytopenia, 1; other, 2) to 50-75% of
the planned dose. Treatment was delayed on 11 occasions
Table II Toxicity
WHO toxicitn grade
0
or unrelated
Toxicity tipe to CBJO-277 1 2 3 4
Nausea vomiting 4 2 9 8
Haemoglobin 18 - 3 1 1
WBC 19 - 3 2 2
Platelets 18 - - 3 2
Alopecia 21 2
Constipation 19 1 2 1
Renal (raised urea. 20 2 1
creatinine,
haematuria)
Liver (raised ALT) 21 - 2
Diarrhoea 20 2 - I
Oral 20 1 2 -
Consciousness 19 3 (lethargy) I -
Infection 20 - 1 2
Others: Mild flushing, I patient; malaise, 2; muffling in ears. 1;
anorexia, 4; moderate shivering 1; tiredness. 1; insomnia. 1 moderate
headache, 1; weakness, 1; sweating, 2.
(nine patients) owing to bed unavailability (2). surgical
intervention (2) and haematological toxicity (5).
There was one objective partial response in a patient with
extensive lymph node disease (duration 18 weeks) in the 22
patients assessable for response. Five patients had static
disease over 1-6 courses (median two courses) before disease
progression. The remaining patients had progressive
disease.
Toxicities
The most frequent toxicities are listed in Table II. The major
toxicities were leucopenia and thrombocytopenia. Septicae-
mia was seen in two patients. Anaemia was also reported,
but only possibly related to the drug as it occurred during
the first cycle of treatment and in most patients was reported
by the clinician as probably unrelated. Nausea and vomiting
was common but usually controlled when ondansetron with
dexamethasone was given. Constipation reported by some
patients was also difficult to assess and may have been
related to the ondansetron and opiates also given, and was
not reported in the phase I studies in which ondansetron was
not used (Foster et al.. 1993a, b). Numerous other minor
symptoms were variously reported during the study but were
of dubious relationship to drug administration and likely to
have been due to disease progression.
Table I Patient characteristics
Total number of patients entered
Total number of eligible patients5
Sex: male female
Age median range (years)
WHO performance status
0
1
2
28
23
12 11
46 (20-70)
5
17
Prior treatment
Surgery 23
Radiotherapy I
None 0
Sites of assessable disease
Primary skin 8
Lymph nodes 13
Lung 3
Liver 4
Bone I
Other 3
Total courses in 23 patients 64
Median courses (range) 2 (1-6)
'Five exclusions because of incorrect diagnosis (1). prior
chemotherapy (2), raised bilirubin on entry (2).
The results of this study are disappointing in that only one
partial responder was seen in the 22 patients with melanoma
who could be assessed following treatment with 12,000 mg
m-2 CBIO-277 given by 24 h infusion every 21 days. This
result is disappointing in view of the anti-tumour efficacy of
its analogue dacarbazine and the three responses in 11
patients documented in the phase I study with CB10-277
given over a short-term infusion (Foster et al., 1993a). In
that phase I study, 8,11 patients had received prior
chemotherapy with a dacarbazine-containing regimen, includ-
ing one of the partial responders to the subsequent CB10-
277. In this present study none of the 22 patients had
received any prior chemotherapy. However, this difference
may be due to chance within the limits of the number of
patients entered.
Pharmacokinetics were not studied in this phase II trial but
had been extensively investigated in the two phase I studies
(Foster et al., 1993a, b). On the basis of those studies it was
believed that the 24 h infusion would permit higher total
drug doses with increased exposure to the active monomethyl
metabolite over that afforded by the short-term infusion. At
the time that the phase I studies were performed, the 5HT3CBIO-277 IN MALIGNANT MELANOMA 777
receptor antagonists currently used as antiemetics were not
generally available. Nausea and vomiting was determined as
the dose-limiting toxicity and influenced the decision to use
the 24 h schedule for this study. Subsequently. ondansetron
(Glaxo) became available and was successfully used in most
of the patients in this study. It might be speculated that in
view of the higher response rate seen in the short-infusion
phase I study, a phase II study using the maximum tolerated
dose over 30min might have elicited further responses,
especially if the nausea and vomiting were controlled by a
more modern antiemetic.
One additional problem with this study is that the o6-
methylguamnne methyltransferase activity of the tumours was
not routinely assessed. A major target of the monomethyl
metabolite of CBIO-277 is o( alkylation of the guanine
residues in DNA (Gibson et al., 1986). The majority of
human tumours possess high activities of the enzyme (Mer+)
and are therefore capable of repairing the DNA alkylation.
The limited efficacy seen in the current study suggests that
many of the 22 patients assessed may have had Mer+
tumours. Supporting this suggestion are data from studies
with human melanoma xenografts where in three tumours
response was related to the level of the o6 methylguamnne
methyltransferase repair protein, the only sensitive tumour
having very low levels (Foster et al., 1990).
The toxicity of the regimen was acceptable. but the lack of
tumour responses does not encourage its use in melanoma in
this 24 h schedule. Furthermore, the recent identification of
temozolomide as an oral monomethyl triazene prodrug
(Newlands et al.. 1992) with activity against melanoma sug-
gests that future studies should concentrate on this agent.
rather than CB1O-277.
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